| 1.53 0.02 (1.32%) | 03-02 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 2.73  |
1-year : | 3.38 |
| Resists | First : | 2.33 |
Second : | 2.9 |
| Pivot price | 1.59 |
|||
| Supports | First : | 1.42 | Second : | 1.18 |
| MAs | MA(5) : | 1.56 |
MA(20) : | 1.68 |
| MA(100) : | 7.03 |
MA(250) : | 8.73 |
|
| MACD | MACD : | -0.8 |
Signal : | -1 |
| %K %D | K(14,3) : | 21.3 |
D(3) : | 24 |
| RSI | RSI(14): 24.4 |
|||
| 52-week | High : | 23.1 | Low : | 1.42 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ MTVA ] has closed above bottom band by 27.3%. Bollinger Bands are 91.3% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 16 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 1.64 - 1.65 | 1.65 - 1.66 |
| Low: | 1.48 - 1.49 | 1.49 - 1.5 |
| Close: | 1.52 - 1.53 | 1.53 - 1.54 |
MetaVia Inc., a clinical-stage biotechnology company focuses on developing and commercializing novel pharmaceuticals to treat cardiometabolic diseases. It develops DA-1241, a novel G-Protein-Coupled Receptor 119 agonist with development optionality as a standalone and/or combination therapy that is in Phase 2a clinical trial for metabolic dysfunction-associated steatohepatitis (MASH), and has completed Phase 1 clinical trial for the treatment of type 2 diabetes mellitus (T2DM); and DA-1726, a novel oxyntomodulin analogue functioning as a GLP-1 receptor and glucagon receptor dual agonist, which is in preclinical development for the treatment of obesity. The company's therapeutic programs include ANA001, a proprietary oral niclosamide formulation for the treatment of patients with moderate COVID-19; NB-01 for the treatment of painful diabetic neuropathy; NB-02 for the treatment of cognitive impairment; and Gemcabene for the treatment of dyslipidemia. It has a license agreement with Pfizer Inc. for the research, development, manufacture, and commercialization of Gemcabene; and joint research agreement with Dong-A ST and ImmunoForge for the development of DA-1726. The company was formerly known as NeuroBo Pharmaceuticals, Inc. and changed its name to MetaVia Inc. in November 2024. MetaVia Inc. is headquartered in Cambridge, Massachusetts.
Wed, 25 Feb 2026
MTVA Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Fri, 16 Jan 2026
MetaVia Announces the Closing of $9.3 Million Underwritten Public Offering, Including Full Exercise of Allotment Option - PR Newswire
Mon, 29 Dec 2025
MetaVia to Participate in and Sponsor the 10th Annual MASH-TAG 2026 Conference - PR Newswire
Tue, 02 Dec 2025
MetaVia Inc. Announces 1-for-11 Reverse Stock Split - PR Newswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 3 (M) |
| Shares Float | 1 (M) |
| Held by Insiders | 55.5 (%) |
| Held by Institutions | 5 (%) |
| Shares Short | 62 (K) |
| Shares Short P.Month | 20 (K) |
| EPS | -10.45 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 2.88 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -58.5 % |
| Return on Equity (ttm) | -168.2 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -5.19 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -16 (M) |
| Levered Free Cash Flow | -11 (M) |
| PE Ratio | -0.15 |
| PEG Ratio | 0 |
| Price to Book value | 0.53 |
| Price to Sales | 0 |
| Price to Cash Flow | -0.32 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|